EA202190853A1 - DLL3 BINDING PROTEINS AND APPLICATIONS - Google Patents
DLL3 BINDING PROTEINS AND APPLICATIONSInfo
- Publication number
- EA202190853A1 EA202190853A1 EA202190853A EA202190853A EA202190853A1 EA 202190853 A1 EA202190853 A1 EA 202190853A1 EA 202190853 A EA202190853 A EA 202190853A EA 202190853 A EA202190853 A EA 202190853A EA 202190853 A1 EA202190853 A1 EA 202190853A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dll3
- proteins
- binding proteins
- dll3 binding
- binding
- Prior art date
Links
Abstract
В изобретении представлены связывающие DLL3 белки и нацеленные на DLL3 мультиспецифические белки (например, нацеленный на DLL3 триспецифический белок), содержащие связывающий CD3 домен, домен продления периода полужизни и связывающий DLL3 домен (например, предусмотренный в настоящем документе связывающий DLL3 белок). Также представлены их фармацевтические композиции, а также нуклеиновые кислоты, рекомбинантные векторы экспрессии и клетки-хозяева для создания таких связывающих DLL3 белков, нацеленных на DLL3 триспецифических белков. Также раскрыты способы применения раскрытых связывающих DLL3 белков, нацеленных на DLL3 триспецифических белков для профилактики и/или лечения заболеваний, состояний и нарушений.The invention provides DLL3 binding proteins and DLL3-targeted multispecific proteins (e.g., a DLL3-targeted trispecific protein) comprising a CD3 binding domain, a half-life extension domain, and a DLL3 binding domain (e.g., the DLL3 binding protein provided herein). Also provided are their pharmaceutical compositions, as well as nucleic acids, recombinant expression vectors, and host cells for generating such DLL3 binding proteins targeting DLL3 trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins targeting DLL3 trispecific proteins for the prevention and/or treatment of diseases, conditions and disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877227P | 2019-07-22 | 2019-07-22 | |
| PCT/US2019/053017 WO2020069028A1 (en) | 2018-09-25 | 2019-09-25 | Dll3 binding proteins and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190853A1 true EA202190853A1 (en) | 2021-12-27 |
Family
ID=80631152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190853A EA202190853A1 (en) | 2019-07-22 | 2019-09-25 | DLL3 BINDING PROTEINS AND APPLICATIONS |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA202190853A1 (en) |
-
2019
- 2019-09-25 EA EA202190853A patent/EA202190853A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090817A1 (en) | TRISSPECIFIC PROTEINS AND METHODS OF THEIR APPLICATION | |
| MX2021003554A (en) | Dll3 binding proteins and methods of use. | |
| EA201792573A1 (en) | TRISPECIFIC RELATED PROTEINS AND METHODS OF THEIR APPLICATION | |
| MX2019006045A (en) | Psma targeting trispecific proteins and methods of use. | |
| EA201892561A1 (en) | HYBRID PROTEINS GDF15 AND THEIR APPLICATION | |
| MX2018010824A (en) | Inducible binding proteins and methods of use. | |
| BR112019023856A2 (en) | triespecific proteins targeting msln and methods of use | |
| MX2021014007A (en) | EpCAM BINDING PROTEINS AND METHODS OF USE. | |
| EA202192910A1 (en) | COMPOUNDS DIRECTED TO PROTEINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR THERAPEUTIC USE | |
| EA202192888A1 (en) | COMPOUNDS AND METHODS FOR TARGETING HUMAN TAU | |
| EA202092086A1 (en) | ARGINASE INHIBITORS | |
| CY1126148T1 (en) | NOVEL CHIMERIC PROTEIN SPECIFIC FOR CD137 AND PD-L1 | |
| EA202090700A1 (en) | REPLICATION-COMPETENT ADENOVIRAL VECTORS | |
| EA202092459A1 (en) | INTERLEUKIN 12 HYBRID PROTEINS, COMPOSITIONS AND METHODS OF THERAPEUTIC APPLICATION, WHICH INCLUDE THEM | |
| EA202092125A1 (en) | ANTIBODIES AGAINST FOLATE 1 RECEPTOR AND THEIR APPLICATION | |
| BR112021024080A2 (en) | rnai constructs to inhibit scap expression and methods of using them | |
| EA202192160A1 (en) | DELIVERY OF POLYNUCLEOTIDE CLN3 USING AN ADENO-ASSOCIATED VIRUS | |
| EA202192488A1 (en) | ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS | |
| EA202190853A1 (en) | DLL3 BINDING PROTEINS AND APPLICATIONS | |
| WO2022256500A3 (en) | Dll3 targeting trispecific proteins and methods of use | |
| EA202092335A1 (en) | COMPOSITIONS BASED ON ERENUMAB AND WAYS OF THEIR APPLICATION | |
| WO2022256498A9 (en) | Msln targeting trispecific proteins and methods of use | |
| EA201992692A1 (en) | MSLN AIMED TRANSPECIFIC PROTEINS AND METHODS OF APPLICATION | |
| EA202092694A1 (en) | SYSTEMS AND METHODS FOR QUANTITATIVE DETERMINATION AND MODIFICATION OF PROTEIN VISCOSITY | |
| EA201991181A1 (en) | PSMA-TARGETED TRANSPECIFIC PROTEINS AND WAYS OF THEIR APPLICATION |